Oncologia
Estudo randomizado | Efeito do canrelizumabe vs. placebo adicionado à quimioterapia na sobrevida e na sobrevida livre de progressão em pacientes com carcinoma esofágico de células escamosas avançado ou metastático.
17 Set, 2021 | 11:55hEffect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge – JAMA Oncology (gratuito por tempo limitado)
Comentário no Twitter
Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival https://t.co/DAlhmtgvv1
— JAMA (@JAMA_current) September 14, 2021
Revisão sistemática | Radiação mamária parcial vs. radioterapia mamária total para câncer de mama precoce.
17 Set, 2021 | 11:50h
Comentário no Twitter
For women with early-stage #BreastCancer, how does giving radiotherapy to part of the breast compare with giving #radiotherapy to the whole breast? The latest Cochrane Review from @CochraneBCancer brings together nine studies, which involved 15,187 women: https://t.co/fVuSrSDAZM pic.twitter.com/QOufZYSH5I
— Cochrane UK (@CochraneUK) September 3, 2021
Relatório de longo prazo de estudo avaliando o uso da radiação após cirurgia excisional de carcinoma ductal in situ de baixo risco.
14 Set, 2021 | 14:11h
Comentário no Twitter
At 15 years, NRG-RTOG 9804 "good risk" breast #DCIS trial shows advantage of radiation therapy over observation to reduce #breastcancer risk https://t.co/l5OWVOb5Dg
#JCO #BCSM #radonc @NRGOnc; @MSK_RadOnc pic.twitter.com/TPAZRheoHT— ASCO Publications (@ASCO_pubs) September 10, 2021
Diretriz ESMO | Câncer de pulmão de células não pequenas precoce e localmente avançado.
14 Set, 2021 | 14:09hRevisão | Terapia endócrina neoadjuvante na prática clínica.
12 Set, 2021 | 21:58hNeoadjuvant Endocrine Therapy in Clinical Practice: A Review – JAMA Oncology (gratuito por tempo limitado)
Revisão sistemática mostra evidência insuficiente de que a inteligência artificial (IA) no rastreamento do câncer de mama seja precisa o bastante para substituir o escrutínio humano.
12 Set, 2021 | 21:39hEstudo original: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ
Comentário no Twitter
A systematic review of #AI for mammography is very disappointing
"Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists"https://t.co/zqFTxojU9J @bmj_latest pic.twitter.com/wylwOsf4ua— Eric Topol (@EricTopol) September 2, 2021
Revisão | Colangiocarcinoma.
12 Set, 2021 | 21:34hCholangiocarcinoma – Nature Reviews Disease Primers (gratuito por tempo limitado)
Infográfico: Cholangiocarcinoma
Comentário no Twitter
Get Primed on #Cholangiocarcinoma with our NEW PrimeView! FREE to download this week! https://t.co/xw8yl29QI4 pic.twitter.com/JKtL6NqnlS
— Nature Reviews Disease Primers (@DiseasePrimers) September 9, 2021
Doença cardiovascular induzida por radiação: revisão de uma patologia sub-reconhecida.
12 Set, 2021 | 20:07hRevisão | Câncer pancreático.
12 Set, 2021 | 20:03hPancreatic Cancer: A Review – JAMA (gratuito por tempo limitado)
Opinião | Biópsia líquida: fé equivocada na detecção precoce do câncer?
8 Set, 2021 | 15:05hLiquid biopsy: misplaced faith in early cancer detection? – STAT
Comentário no Twitter
Opinion: "The real money isn’t in testing the relatively few people with advanced cancer, it’s in testing everyone else: those not known to have cancer." Screening liquid biopsies could become standard care before we know if they save lives https://t.co/1IAo5Kb0vm via @statnews
— Gideon Gil (@GideonGil) August 31, 2021